Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Outcome and recovery trajectories for intracerebral hemorrhage in adults with primary immune thrombocytopenia

Peng Zhao, Ming Hou, Yi Liu, Ru Feng, Yujun Dong, Hai-Xia Fu, Qiu-Sha Huang, Jin Wu, Zhuoyu An, Yuanyuan Zhang, Xiangyu Zhao, Ying-jun Chang, Lan-Ping Xu, Xiaojun Huang, Xiaohui Zhang

Blood (2025) 146 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2025-3033

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

A Phase II study of time-limited treatment with orelabrutinib plus bendamustine and obinutuzumab (OBG) in patients with treatment-Naïve CLL/SLL patients

Xutao Guo, Yunxia Zhang, Xiaolei Wei, Haohao Lei, Qi Wei, Yongqiang Wei, Dongsheng Wu, Ning Su, Ru Feng

Blood (2025) 146 (Supplement 1): 7417.

https://doi.org/10.1182/blood-2025-7417

Published: 2025

Journal Articles

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

Yan Gao, Li-Qin Ping, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2025-5375

Published: 2025

Journal Articles

Risk factors and outcomes of carbapenem-resistant and multidrug-resistant klebsiella pneumoniae bloodstream infection in patients with acute leukemia

Youhai Yuan, Shanshan Zhang, Yongqiang Wei, Ru Feng, Xiaolei Wei

Blood (2025) 146 (Supplement 1): 6930.

https://doi.org/10.1182/blood-2025-6930

Published: 2025

Journal Articles

CHN1 suppresses B-cell non-Hodgkin lymphoma progression via akt/mTOR pathway

Xiaoya Yun, Weidong Ding, Yifan Liu, Ru Feng, Jiangtao Li, Hui Liu

Blood (2025) 146 (Supplement 1): 6776.

https://doi.org/10.1182/blood-2025-6776

Published: 2025

Journal Articles

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Blood (2025) 146 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2025-1902

Published: 2025

Journal Articles

A chemotherapy-free regimen of sintilimab, rituximab, and lenalidomide ± polatuzumab vedotin in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Hanzhen Zhang, Xutao Guo, Qi Wei, Yongqiang Wei, Ru Feng, Xiaolei Wei

Blood (2025) 146 (Supplement 1): 5478.

https://doi.org/10.1182/blood-2025-5478

Published: 2025

Journal Articles

Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China

Xutao Guo, Yongqiang Wei, Xiaolei Wei, Qi Wei, Ru Feng

Blood (2025) 146 (Supplement 1): 7421.

https://doi.org/10.1182/blood-2025-7421

Published: 2025

Journal Articles

Efficacy and Safety of Venetoclax Combine Azacitidine for Acute Myeloid Leukemia in China: A Real-World Single-Center Study

Jiefei Bai, Hui Liu, Jiangtao Li, Ting Wang, Chunli Zhang, Yazi Yang, Xiaoya Yun, Jingjing Yin, Long Qian, Fei Zhao, Ru Feng, Hongmei Jing

Blood (2024) 144 (Supplement 1): 7896.

https://doi.org/10.1182/blood-2024-193714

Published: 2024

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2024-204915

Published: 2024

Journal Articles

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Yuqi Wang, Chen Huan, Zhang Hanzhen, Shanshan Zhang, Youhai Yuan, Ru Feng, Yongqiang Wei, Xiaolei Wei

Blood (2024) 144 (Supplement 1): 7031.

https://doi.org/10.1182/blood-2024-205810

Published: 2024

Journal Articles

Genetic Characteristics of Patients Aged ≥80 Years with Diffuse Large B-Cell Lymphoma

Xiaoya Yun, Jiefei Bai, Ru Feng, Hongmei Jing, Hui Liu

Blood (2024) 144 (Supplement 1): 6228.

https://doi.org/10.1182/blood-2024-207720

Published: 2024

Journal Articles

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Xutao Guo, Yunxia Zhang, Haohao Lei, Yongqiang Wei, Xiaolei Wei, Qi Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2024-201948

Published: 2024

Journal Articles

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Yutian Yang, Minglang Zhan, Zhang Hanzhen, Xiaolei Wei, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 6244.

https://doi.org/10.1182/blood-2024-198161

Published: 2024

Journal Articles

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Xutao Guo, Xiaolei Wei, Yongqiang Wei, Qi Wei, Ning Su, Yunxia Zhang, Haohao Lei, Ru Feng

Blood (2024) 144 (Supplement 1): 6776.

https://doi.org/10.1182/blood-2024-207666

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Zhang Hanzhen, Yongqiang Wei, Xiaolei Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 6456.

https://doi.org/10.1182/blood-2024-201377

Published: 2024

Journal Articles

Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

Menglin Li, HaiXia Fu, Hui Liu, Ru Feng, Yi Liu, Jingwen Wang, Lei Yang, Zhao Wang, Gaochao Zhang, Qingyuan Qu, Yuxiu Chen, Jianying Zhou, Mengyu Xiao, Lulu Wang, Mengtong Zang, Yun He, Xiaolu Zhu, Xiaosu Zhao, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 712.

https://doi.org/10.1182/blood-2024-198335

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcome and recovery trajectories for intracerebral hemorrhage in adults with primary immune thrombocytopenia

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

A Phase II study of time-limited treatment with orelabrutinib plus bendamustine and obinutuzumab (OBG) in patients with treatment-Naïve CLL/SLL patients

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

Risk factors and outcomes of carbapenem-resistant and multidrug-resistant klebsiella pneumoniae bloodstream infection in patients with acute leukemia

CHN1 suppresses B-cell non-Hodgkin lymphoma progression via akt/mTOR pathway

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

A chemotherapy-free regimen of sintilimab, rituximab, and lenalidomide ± polatuzumab vedotin in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China

Efficacy and Safety of Venetoclax Combine Azacitidine for Acute Myeloid Leukemia in China: A Real-World Single-Center Study

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Genetic Characteristics of Patients Aged ≥80 Years with Diffuse Large B-Cell Lymphoma

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only